PRLD — Prelude Therapeutics Share Price
0.000.00%
Last trade - 00:00- $408.59m
- $175.65m
- 36
- 25
- 60
- 35
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.72 | ||
| Price to Tang. Book | 1.72 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -51.7% | ||
| Return on Equity | -56.33% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
Directors
- Paul Friedman NEC (78)
- Krishna Vaddi CEO (55)
- Laurent Chardonnet CFO (57)
- Andrew Combs EVP (54)
- Deborah Morosini EVP (62)
- Peggy Scherle CSO (59)
- David Mauro OTH (55)
- Martin Babler DRC (56)
- Julian Baker IND (54)
- David Bonita IND (45)
- Mardi Dier IND (57)
- Victor Sandor IND (54)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 5th, 2016
- Public Since
- September 25th, 2020
- No. of Shareholders
- 17
- No. of Employees
- 128
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 54,920,594
- Address
- 175 Innovation Boulevard, WILMINGTON, 19805
- Web
- https://preludetx.com/
- Phone
- +1 3024671280
- Auditors
- Ernst & Young LLP
Upcoming Events for PRLD
Prelude Therapeutics Inc Annual Shareholders Meeting
Q2 2024 Prelude Therapeutics Inc Earnings Release
Similar to PRLD
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Prelude Therapeutics share price?
As of Today at 19:17 UTC, shares in Prelude Therapeutics are trading at $3.72. This share price information is delayed by 15 minutes.
How has the Prelude Therapeutics share price performed this year?
Shares in Prelude Therapeutics last closed at $3.72 and the price had moved by -37.79% over the past 365 days. In terms of relative price strength the Prelude Therapeutics share price has underperformed the S&P500 Index by -48.23% over the past year.
What are the analyst and broker recommendations for Prelude Therapeutics?
The overall consensus recommendation for Prelude Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Prelude Therapeutics dividend yield?
Prelude Therapeutics does not currently pay a dividend.
Does Prelude Therapeutics pay a dividend?
Prelude Therapeutics does not currently pay a dividend.
When does Prelude Therapeutics next pay dividends?
Prelude Therapeutics does not currently pay a dividend.
How do I buy Prelude Therapeutics shares?
To buy shares in Prelude Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Prelude Therapeutics?
As of the previous close price of $3.72, shares in Prelude Therapeutics had a market capitalisation of $408.59m.
Where are Prelude Therapeutics shares listed?
Here are the trading details for Prelude Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: PRLD
What kind of share is Prelude Therapeutics?
Based on an overall assessment of its quality, value and momentum Prelude Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Prelude Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Prelude Therapeutics is $5.80. That is 55.91% above the last closing price of $3.72.
Analysts covering Prelude Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.00 for the next financial year.
What is the trend in the Prelude Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Prelude Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +32.14%.
As of the last closing price of $3.72, shares in Prelude Therapeutics were trading +2.32% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Prelude Therapeutics PE Ratio?
The Prelude Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.72.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Prelude Therapeutics?
Prelude Therapeutics' management team is headed by:
- Paul Friedman - NEC
- Krishna Vaddi - CEO
- Laurent Chardonnet - CFO
- Andrew Combs - EVP
- Deborah Morosini - EVP
- Peggy Scherle - CSO
- David Mauro - OTH
- Martin Babler - DRC
- Julian Baker - IND
- David Bonita - IND
- Mardi Dier - IND
- Victor Sandor - IND